Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells

Inclusion criteria 1. Age is 18-75 years old, and gender is unlimited; 2. HCC was confirmed by pathological or clinical examination; 3. Patients with stage CNLCIII, IV primary HCC who are receiving second-line treatment / unable to receive existing treatments, or CNLCI and II of primary HCC patients who are unable to receive existing treatments; 4. Male subjects with partner women of childbearing age must have reliable, effective methods of contraception starting from the signing of the informed consent form until 120 days after the last dose of the study drug. Male subjects with a pregnant spouse must use condoms without other contraceptive methods; 5. Participants volunteered to join the study, signed an informed consent, had good compliance, and cooperated with the follow-up. Exclusion criteria 1. Gastrointestinal bleeding, refractory ascites, hepatic encephalopathy, or hepatorenal syndrome; 2. Accept other cellular or immune clinical experiments within 8 weeks before enrollment; 3. Immunological deficiency, a known immunosuppressive disease or HIV; 4. Active infection, unexplained fever; 5. Serious or unstable heart, lung, kidney and hematopoietic system diseases; 6. Autoimmune diseases, such as rheumatoid arthritis; 7. Neurological diseases, diffuse leptomeningeal diseases; combined with neurodegenerative diseases; 8. Hormone use during cell therapy: dexamethasone dose exceeds 2mg / day during immunotherapy; 9. Pregnant or lactating women; 10. The subject had a known history of psychotropic substance abuse or drug use; he had stopped drinking Patients can be enrolled; 11 In the judgment of the investigator, the subject has other factors that may cause the forced termination of the study, such as other serious diseases or serious abnormal laboratory examination or other family or social factors that will affect the subject's safety of the subject, or the collection of trial data and samples.